Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 6/20 | 0.62 |
| ▸ | NPY2R | P49146 | 8/20 | 0.60 |
| ▸ | NPY4R | P50391 | 8/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.60 |
| ▸ | NPY1R | P25929 | 6/20 | 0.60 |
| ▸ | F2 | P00734 | 4/20 | 0.58 |
| ▸ | GLP1R | P43220 | 1/20 | 0.57 |
| ▸ | GCGR | P47871 | 1/20 | 0.57 |
| ▸ | GIPR | P48546 | 1/20 | 0.57 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182783 | 0.93 | CALCR (0.63) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31182798 | 0.92 | CALCR (0.64) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30607467 | 0.91 | CALCR (0.64) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30975049 | 0.91 | CALCR (0.65) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30567780 | 0.91 | F2 (0.60) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31182472 | 0.89 | NPY2R (0.66) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30906377 | 0.89 | NPY2R (0.71) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30277958 | 0.89 | NPY2R (0.62) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29588486 | 0.89 | NPY2R (0.65) | NPY2RNPY4RNPY5RNPY1RF2 | |
| SCHEMBL30437207 | 0.89 | CALCR (0.61) | CALCRNPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | TWINPIG BIOLAB INC. (KR) | 2026-01-01 | — | — | US | claimed |
| US-20250228951-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | TWINPIG BIOLAB INC. (KR) | 2025-07-17 | — | — | US | claimed |
| WO-2025106551-A1 | HYDROGEL COMPOSITIONS COMPRISING SYNERGISTIC ANTIMICROBIAL PEPTIDES (AMPS) AND METHODS OF MAKING SAME | ROWAN UNIVERSITY (US) | 2025-05-22 | — | — | WO | claimed |
| EP-4512411-A2 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | Twinpig Biolab, Inc. (KR) | 2025-02-26 | — | — | EP | claimed |
| EP-4512410-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | Twinpig Biolab, Inc. (KR) | 2025-02-26 | — | — | EP | claimed |
| WO-2023195805-A9 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | 트윈피그바이오랩(주) | 2024-07-11 | — | — | WO | claimed |
| US-20240009321-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2024-01-11 | — | — | US | claimed |
| CN-117180202-A | Endoplasmic reticulum targeted liposome, and preparation method and application thereof | 山东大学 | 2023-12-08 | — | — | CN | claimed |
| CN-117085146-A | Metal framework preparation method and application of metal framework in targeted activation of endoplasmic reticulum stress | 湖北医药学院 | 2023-11-21 | — | — | CN | claimed |
| WO-2023195805-A2 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | 트윈피그바이오랩(주) | 2023-10-12 | — | — | WO | claimed |
| WO-2023195802-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | 트윈피그바이오랩(주) | 2023-10-12 | — | — | WO | claimed |
| CN-116789961-A | Endoplasmic reticulum targeted single-chain cyclic poly (beta-amino ester), preparation method and application | 复旦大学附属儿科医院 | 2023-09-22 | — | — | CN | claimed |
| CN-115996942-A | Macrophage-targeting peptides, conjugates, compositions and uses thereof | 双亥生命科学株式会社 | 2023-04-21 | — | — | CN | claimed |
| EP-4103585-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | Twinpig Biolab, Inc. (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20220354957-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | US | claimed |
| WO-2022234346-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | WO | claimed |
| US-11484601-B2 | Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide | TWINPIGBIOLAB INC. (KR) | 2022-11-01 | — | — | US | claimed |
| WO-2022115488-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-02 | — | — | WO | claimed |
| CN-114469861-A | Construction and application of vitamin E nano-carrier capable of reversing alcoholic liver disease | 浙江大学 | 2022-05-13 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | ITGB8, ITGB2, ITGA8 | CALCR 257/4885NPY2R 751/4885NPY4R 1155/4885 |
| US-20240009321-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | SGMS1, SGMS2, SMPD3 | CALCR 3591/4885NPY2R 4776/4885NPY4R 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.